Brief: Polypid Says Positive Recommendation By DSMB To Continue Enrollment Of Phase 3 Shield II Trial Of D-Plex₁₀₀ To 800 Patients; Concurrent Private Placement Upto $41 Mln

Polypid

24/12/2024 24:26

Dec 23 (Reuters) - PolyPid Ltd  PYPD.O :
    * POLYPID ANNOUNCES POSITIVE RECOMMENDATION BY DSMB TO
CONTINUE
ENROLLMENT OF PHASE 3 SHIELD II TRIAL OF D-PLEX₁₀₀ TO 800
PATIENTS WITH A CONCURRENT PRIVATE PLACEMENT OF UP TO $41
MILLION
    * POLYPID LTD - 630 PATIENTS ENROLLED, COMPLETION EXPECTED
Q1
2025, RESULTS Q2 2025

Source text:  ID:nGNX7W1SVR 
Further company coverage:  PYPD.O 

 ((Reuters.Briefs@thomsonreuters.com;))